Current pharmacologic treatment of dementia: A clinical practice guideline from the American college of physicians and the American academy of family physicians

Amir Qaseem, Vincenza Snow, J. Thomas Cross, Mary Ann Forciea, Robert Hopkins, Paul Shekelle, Alan Adelman, David Mehr, Kenneth Schellhase, Doug Campos-Outcalt, Pasqualina Santaguida, Douglas K. Owens, Donald E. Casey, Paul Dallas, Nancy C. Dolan, Lakshmi Halasyamani, Robert H. Hopkins, Eric M. Wall, Jonathan E. Rodnick, Kenneth G. SchellhaseSteven W. Strode, Kurtis S. Elward, James W. Mold, Jonathan L. Temte, Frederick M. Chen, Thomas F. Koinis, Donya A. Powers, James M. Gill, Kevin Peterson, Robert C. Marshall, Herbert F. Young, Bellinda K. Schoof

Research output: Contribution to journalReview article

241 Citations (Scopus)

Abstract

Description: The American College of Physicians and American Academy of Family Physicians developed this guideline to present the available evidence on current pharmacologic treatment of dementia. Methods: The targeted literature search included evidence related to the effectiveness of 5 U.S. Food and Drug Administration-approved pharmacologic therapies for dementia for outcomes in the domains of cognition, global function, behavior/mood, and quality of life/activities of daily living. Recommendation 1: Clinicians should base the decision to initiate a trial of therapy with a cholinesterase inhibitor or memantine on individualized assessment. (Grade: weak recommendation, moderate-quality evidence.) Recommendation 2: Clinicians should base the choice of pharmacologic agents on tolerability, adverse effect profile, ease of use, and cost of medication. The evidence is insufficient to compare the effectiveness of different pharmacologic agents for the treatment of dementia. (Grade: weak recommendation, low-quality evidence.) Recommendation 3: There is an urgent need for further research on the clinical effectiveness of pharmacologic management of dementia.

Original languageEnglish (US)
Pages (from-to)370-378
Number of pages9
JournalAnnals of internal medicine
Volume148
Issue number5
DOIs
StatePublished - Mar 4 2008

Fingerprint

Family Physicians
Practice Guidelines
Dementia
Physicians
Memantine
Cholinesterase Inhibitors
United States Food and Drug Administration
Therapeutics
Activities of Daily Living
Cognition
Quality of Life
Guidelines
Costs and Cost Analysis
Research

Cite this

Current pharmacologic treatment of dementia : A clinical practice guideline from the American college of physicians and the American academy of family physicians. / Qaseem, Amir; Snow, Vincenza; Cross, J. Thomas; Forciea, Mary Ann; Hopkins, Robert; Shekelle, Paul; Adelman, Alan; Mehr, David; Schellhase, Kenneth; Campos-Outcalt, Doug; Santaguida, Pasqualina; Owens, Douglas K.; Casey, Donald E.; Dallas, Paul; Dolan, Nancy C.; Halasyamani, Lakshmi; Hopkins, Robert H.; Wall, Eric M.; Rodnick, Jonathan E.; Schellhase, Kenneth G.; Strode, Steven W.; Elward, Kurtis S.; Mold, James W.; Temte, Jonathan L.; Chen, Frederick M.; Koinis, Thomas F.; Powers, Donya A.; Gill, James M.; Peterson, Kevin; Marshall, Robert C.; Young, Herbert F.; Schoof, Bellinda K.

In: Annals of internal medicine, Vol. 148, No. 5, 04.03.2008, p. 370-378.

Research output: Contribution to journalReview article

Qaseem, A, Snow, V, Cross, JT, Forciea, MA, Hopkins, R, Shekelle, P, Adelman, A, Mehr, D, Schellhase, K, Campos-Outcalt, D, Santaguida, P, Owens, DK, Casey, DE, Dallas, P, Dolan, NC, Halasyamani, L, Hopkins, RH, Wall, EM, Rodnick, JE, Schellhase, KG, Strode, SW, Elward, KS, Mold, JW, Temte, JL, Chen, FM, Koinis, TF, Powers, DA, Gill, JM, Peterson, K, Marshall, RC, Young, HF & Schoof, BK 2008, 'Current pharmacologic treatment of dementia: A clinical practice guideline from the American college of physicians and the American academy of family physicians', Annals of internal medicine, vol. 148, no. 5, pp. 370-378. https://doi.org/10.7326/0003-4819-148-5-200803040-00008
Qaseem, Amir ; Snow, Vincenza ; Cross, J. Thomas ; Forciea, Mary Ann ; Hopkins, Robert ; Shekelle, Paul ; Adelman, Alan ; Mehr, David ; Schellhase, Kenneth ; Campos-Outcalt, Doug ; Santaguida, Pasqualina ; Owens, Douglas K. ; Casey, Donald E. ; Dallas, Paul ; Dolan, Nancy C. ; Halasyamani, Lakshmi ; Hopkins, Robert H. ; Wall, Eric M. ; Rodnick, Jonathan E. ; Schellhase, Kenneth G. ; Strode, Steven W. ; Elward, Kurtis S. ; Mold, James W. ; Temte, Jonathan L. ; Chen, Frederick M. ; Koinis, Thomas F. ; Powers, Donya A. ; Gill, James M. ; Peterson, Kevin ; Marshall, Robert C. ; Young, Herbert F. ; Schoof, Bellinda K. / Current pharmacologic treatment of dementia : A clinical practice guideline from the American college of physicians and the American academy of family physicians. In: Annals of internal medicine. 2008 ; Vol. 148, No. 5. pp. 370-378.
@article{956575485c3543eab05d6c9691f1dac5,
title = "Current pharmacologic treatment of dementia: A clinical practice guideline from the American college of physicians and the American academy of family physicians",
abstract = "Description: The American College of Physicians and American Academy of Family Physicians developed this guideline to present the available evidence on current pharmacologic treatment of dementia. Methods: The targeted literature search included evidence related to the effectiveness of 5 U.S. Food and Drug Administration-approved pharmacologic therapies for dementia for outcomes in the domains of cognition, global function, behavior/mood, and quality of life/activities of daily living. Recommendation 1: Clinicians should base the decision to initiate a trial of therapy with a cholinesterase inhibitor or memantine on individualized assessment. (Grade: weak recommendation, moderate-quality evidence.) Recommendation 2: Clinicians should base the choice of pharmacologic agents on tolerability, adverse effect profile, ease of use, and cost of medication. The evidence is insufficient to compare the effectiveness of different pharmacologic agents for the treatment of dementia. (Grade: weak recommendation, low-quality evidence.) Recommendation 3: There is an urgent need for further research on the clinical effectiveness of pharmacologic management of dementia.",
author = "Amir Qaseem and Vincenza Snow and Cross, {J. Thomas} and Forciea, {Mary Ann} and Robert Hopkins and Paul Shekelle and Alan Adelman and David Mehr and Kenneth Schellhase and Doug Campos-Outcalt and Pasqualina Santaguida and Owens, {Douglas K.} and Casey, {Donald E.} and Paul Dallas and Dolan, {Nancy C.} and Lakshmi Halasyamani and Hopkins, {Robert H.} and Wall, {Eric M.} and Rodnick, {Jonathan E.} and Schellhase, {Kenneth G.} and Strode, {Steven W.} and Elward, {Kurtis S.} and Mold, {James W.} and Temte, {Jonathan L.} and Chen, {Frederick M.} and Koinis, {Thomas F.} and Powers, {Donya A.} and Gill, {James M.} and Kevin Peterson and Marshall, {Robert C.} and Young, {Herbert F.} and Schoof, {Bellinda K.}",
year = "2008",
month = "3",
day = "4",
doi = "10.7326/0003-4819-148-5-200803040-00008",
language = "English (US)",
volume = "148",
pages = "370--378",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "5",

}

TY - JOUR

T1 - Current pharmacologic treatment of dementia

T2 - A clinical practice guideline from the American college of physicians and the American academy of family physicians

AU - Qaseem, Amir

AU - Snow, Vincenza

AU - Cross, J. Thomas

AU - Forciea, Mary Ann

AU - Hopkins, Robert

AU - Shekelle, Paul

AU - Adelman, Alan

AU - Mehr, David

AU - Schellhase, Kenneth

AU - Campos-Outcalt, Doug

AU - Santaguida, Pasqualina

AU - Owens, Douglas K.

AU - Casey, Donald E.

AU - Dallas, Paul

AU - Dolan, Nancy C.

AU - Halasyamani, Lakshmi

AU - Hopkins, Robert H.

AU - Wall, Eric M.

AU - Rodnick, Jonathan E.

AU - Schellhase, Kenneth G.

AU - Strode, Steven W.

AU - Elward, Kurtis S.

AU - Mold, James W.

AU - Temte, Jonathan L.

AU - Chen, Frederick M.

AU - Koinis, Thomas F.

AU - Powers, Donya A.

AU - Gill, James M.

AU - Peterson, Kevin

AU - Marshall, Robert C.

AU - Young, Herbert F.

AU - Schoof, Bellinda K.

PY - 2008/3/4

Y1 - 2008/3/4

N2 - Description: The American College of Physicians and American Academy of Family Physicians developed this guideline to present the available evidence on current pharmacologic treatment of dementia. Methods: The targeted literature search included evidence related to the effectiveness of 5 U.S. Food and Drug Administration-approved pharmacologic therapies for dementia for outcomes in the domains of cognition, global function, behavior/mood, and quality of life/activities of daily living. Recommendation 1: Clinicians should base the decision to initiate a trial of therapy with a cholinesterase inhibitor or memantine on individualized assessment. (Grade: weak recommendation, moderate-quality evidence.) Recommendation 2: Clinicians should base the choice of pharmacologic agents on tolerability, adverse effect profile, ease of use, and cost of medication. The evidence is insufficient to compare the effectiveness of different pharmacologic agents for the treatment of dementia. (Grade: weak recommendation, low-quality evidence.) Recommendation 3: There is an urgent need for further research on the clinical effectiveness of pharmacologic management of dementia.

AB - Description: The American College of Physicians and American Academy of Family Physicians developed this guideline to present the available evidence on current pharmacologic treatment of dementia. Methods: The targeted literature search included evidence related to the effectiveness of 5 U.S. Food and Drug Administration-approved pharmacologic therapies for dementia for outcomes in the domains of cognition, global function, behavior/mood, and quality of life/activities of daily living. Recommendation 1: Clinicians should base the decision to initiate a trial of therapy with a cholinesterase inhibitor or memantine on individualized assessment. (Grade: weak recommendation, moderate-quality evidence.) Recommendation 2: Clinicians should base the choice of pharmacologic agents on tolerability, adverse effect profile, ease of use, and cost of medication. The evidence is insufficient to compare the effectiveness of different pharmacologic agents for the treatment of dementia. (Grade: weak recommendation, low-quality evidence.) Recommendation 3: There is an urgent need for further research on the clinical effectiveness of pharmacologic management of dementia.

UR - http://www.scopus.com/inward/record.url?scp=41049104686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41049104686&partnerID=8YFLogxK

U2 - 10.7326/0003-4819-148-5-200803040-00008

DO - 10.7326/0003-4819-148-5-200803040-00008

M3 - Review article

C2 - 18316755

AN - SCOPUS:41049104686

VL - 148

SP - 370

EP - 378

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 5

ER -